Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents
22. Dezember 2015 16:05 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Doses First Patient in Phase 3 Clinical Trial of Taksta(TM) in Acute Bacterial Skin and Skin Structure Infections
08. Dezember 2015 07:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Dec. 8, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company developing antibiotics to meet critical medical needs in the treatment of...
Cempra to Present Anti-NASH Data for Solithromycin at The Liver Meeting(R) 2015
11. November 2015 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present at Two Upcoming Investor Conferences
10. November 2015 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present Solithromycin Oral Data at CHEST 2015
23. Oktober 2015 09:24 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 23, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports Third Quarter 2015 Financial Results and Provides Corporate Update
22. Oktober 2015 07:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Report Third Quarter 2015 Financial Results
19. Oktober 2015 08:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces Positive Topline Phase 3 Clinical Results for Intravenous Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
16. Oktober 2015 07:00 ET
|
Melinta Therapeutics, Inc.
Solithromycin Met All FDA Primary Objectives of Non-Inferiority Compared to Moxifloxacin
Two Phase 3 Trials Required by the FDA and the EMA for CABP Regulatory Filings Now Complete
Rolling NDA...
Cempra to Present Solithromycin Data at ID Week 2015
05. Oktober 2015 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present Solithromycin Data in COPD Patient Subgroup at European Respiratory Society International Congress
24. September 2015 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...